Holen Sie sich die Stockscreener-App
23.30
8.22%
1.77
Schlusskurs vom Vortag:
$21.53
Offen:
$21.51
24-Stunden-Volumen:
1.02M
Relative Volume:
2.40
Marktkapitalisierung:
$346.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+50.03%
1M Leistung:
+0.78%
6M Leistung:
-38.47%
1J Leistung:
-27.19%
1-Tages-Spanne:
$20.96
$26.48
1-Wochen-Bereich:
$15.16
$26.48
52-Wochen-Spanne:
$14.42
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
23.30 | 346.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene Inc [NASDAQ: NGNE] Sees Increase in Stock Value - Knox Daily
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Neurogene Inc (NGNE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - Victoria Advocate
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Barclays PLC Purchases 11,316 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Progress in Rett Syndrome Program - TipRanks
Jane Street Group LLC Invests $324,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives $60.83 Average PT from Analysts - MarketBeat
7,050 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Franklin Resources Inc. - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Sells 1,463 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Acquires 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Buys 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Charles Schwab Investment Management Inc. Buys 741 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
MetLife Investment Management LLC Invests $254,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Insider SignalsDec 3 - substack.com
Neurogene files to sell 4M shares of common stock for holders - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out - AccessWire
Neurogene Inc. sees significant stock purchases by Samsara BioCapital - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
CEO Rachel Mcminn Increases Stake in Neurogene Inc with Recent S - GuruFocus.com
Neurogene retains stock target, buy rating amid Rett syndrome trial data - Investing.com Canada
Insider Buying: Christine Cvijic Acquires 24,000 Shares of Neuro - GuruFocus.com
Neurogene president buys $491,400 in company stock By Investing.com - Investing.com Nigeria
Neurogene CEO Rachel McMinn acquires $968,999 in stock By Investing.com - Investing.com Nigeria
Neurogene president buys $491,400 in company stock - Investing.com
Neurogene CEO Rachel McMinn acquires $968,999 in stock - Investing.com India
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):